GSK Signs Drug Discovery Deal with AI Company Exscientia
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 7 (Table of Contents)
Published: 12 Jul-2017
DOI: 10.3833/pdr.v2017.i7.2261 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In pursuit of novel, selective small molecules, GlaxoSmithKline (GSK) has signed a deal with Exscientia to utilise the latter’s artificial intelligence (AI)-driven drug discovery platform to develop up to 10 new drugs for undisclosed disease-related targets which are selected by GSK...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS